The EMBO Journal4 分钟
Cholesterol restriction primes antiviral innate immunity via SREBP1-driven noncanonical ...
Cholesterol restriction-mediated SREBP1 activation induces noncanonical type I IFNs, including IFN-ω and minor IFN-α subsets, ...
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for ...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused ...